Asian Pacific Journal of Cancer Prevention

  • 제14권2호
  • /
  • Pages.691-694
  • /
  • 2013
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Meta-analysis of the Efficacy of Sorafenib for Hepatocellular Carcinoma

  • Wang, Zhao (Department of Digestion,Chengdu Military General Hospital) ;
  • Wu, Xiao-Ling (Department of Digestion,Chengdu Military General Hospital) ;
  • Zeng, Wei-Zheng (Department of Digestion,Chengdu Military General Hospital) ;
  • Xu, Gui-Sen (Department of Emergency, Chengdu Military General Hospital) ;
  • Xu, Hui (Department of Digestion,Chengdu Military General Hospital) ;
  • Weng, Min (Department of Digestion,Chengdu Military General Hospital) ;
  • Hou, Juan-Ni (Department of Digestion,Chengdu Military General Hospital) ;
  • Jiang, Ming-De (Department of Digestion,Chengdu Military General Hospital)
  • 발행 : 2013.02.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: By carrying out a meta-analysis of randomized controlled trials that compared sorafenib or combined chemotherapy with placebo or combined chemotherapy, the effectiveness of sorafenib in hepatocellular carcinoma was evaluated in the present study, which also provided clinical practice guidelines of evidence-based-medicine. Methods: We reviewed PubMed citations concerning sorafenib treating hepatocellular carcinoma in randomized controlled trials from Jan 2000 to July 2012. All the literature was extracted by Cochrane systematic reviews and underwent meta-analysis with RewMan 5.0 software. Results: Finally, four papers documenting randomized controlled studies were included. Compared with controls, sorafenib was shown to significantly increase overall survival (OS), time to progression (TTP), and disease control rates (DCR), but not the time to symptom progression (TTSP) in hepatocellular carcinoma patients. The incidence of grade-III/IV adverse reactions, including hand-foot-skin reactions, diarrhea, hypertension and skin rash or desquamation, in sorafenib treatment group was higher than that in controls. However, there was no significant difference in the incidence of hypodynamia between the two groups. Conclusions: Sorafenib exerts significant curative effects in hepatocellular carcinoma.

키워드

참고문헌

  1. Abou-Alfa GK, Johnson P, Knox JJ, et al (2010). Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma. JAMA, 304, 2154-60. https://doi.org/10.1001/jama.2010.1672
  2. Chen KF, Chen HL, Tai WT, et al (2011). Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmcol Exp Ther, 337, 155-61. https://doi.org/10.1124/jpet.110.175786
  3. Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
  4. Dal Lago L, D'Hondt V, Awada A (2008). Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist, 13, 845-58. https://doi.org/10.1634/theoncologist.2007-0233
  5. Escudier B, Eisen T, Stadler WM, et al (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med, 356, 125-34. https://doi.org/10.1056/NEJMoa060655
  6. Escudier B, Eisen T, Stadler WM, et al (2009). Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol, 27, 3312-8. https://doi.org/10.1200/JCO.2008.19.5511
  7. Furuse J, Ishii H, Nakachi K, et al (2008). Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci, 99, 159-65.
  8. Huitzil-Melendez F, Saltz L, Song J, et al (2008). Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients (pts) with hepatitis C (C+) versus B (B+) treated with sorafenib (S). In: 2007 Gastrointestinal Cancers Symposium.
  9. Jemal A, Murray T, Ward E, et al (2005). Cancer statistics, 2005. CA Cancer J Clin, 55, 10-30. https://doi.org/10.3322/canjclin.55.1.10
  10. Kudo M, Imanaka K, Chida N, et al (2011). Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer, 47, 2117-27. https://doi.org/10.1016/j.ejca.2011.05.007
  11. Liu L, Cao Y, Chen C, et al (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res, 66, 11851-8. https://doi.org/10.1158/0008-5472.CAN-06-1377
  12. Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in advanced hepatocellular carcinoma. New Engl J Med, 359, 378-90. https://doi.org/10.1056/NEJMoa0708857
  13. Parkin DM, Pisani P, Ferlay J (2008). Global cancer statistics. CA Cancer J Clin, 49, 33-64.
  14. Villanueva A, Newell P, Chiang DY, et al (2007). Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis, 27, 55-76. https://doi.org/10.1055/s-2006-960171
  15. Wilhelm S, Carter C, Lynch M, et al (2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 5, 835-44. https://doi.org/10.1038/nrd2130

피인용 문헌

  1. Prognostic Significance of the Peripheral Blood Absolute Monocyte Count in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma Receiving Systemic Chemotherapy vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6387
  2. Sorafenib Continuation after First Disease Progression Could Reduce Disease Flares and Provide Survival Benefits in Patients with Hepatocellular Carcinoma: a Pilot Retrospective Study vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3151
  3. An Updated Meta-Analysis of Randomized Controlled Trials Assessing the Effect of Sorafenib in Advanced Hepatocellular Carcinoma vol.9, pp.12, 2014, https://doi.org/10.1371/journal.pone.0112530
  4. Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma vol.36, pp.11, 2015, https://doi.org/10.1007/s13277-015-3632-7
  5. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma vol.12, pp.6, 2017, https://doi.org/10.1007/s11523-017-0522-5